NewsSource: EClinCloud Official Website Historical Archive

Congratulations to Trinomab on the Marketing Approval of Siltartoxatug! Supported by EClinCloud eCOA

1 min readEClinCloud Editorial Team
Archive article cover: Congratulations to Trinomab on the marketing approval of siltartoxatug, supported by EClinCloud eCOA

 

国家药监局2025年2月药品批准证明文件送达信息  

Screenshot source: NMPA official website

 

On February 11, Xintituo® (generic name: siltartoxatug injection)—a world-first recombinant anti-tetanus toxin monoclonal antibody drug independently developed by Zhuhai Trinomab Pharmaceutical Co., Ltd. ("Trinomab")—was formally approved for marketing by China's National Medical Products Administration (NMPA). Notably, it is the world's first recombinant fully human monoclonal antibody in the field of tetanus prevention and will fundamentally change the current landscape of tetanus prevention, offering safer and more effective protection for patients worldwide.

Xintituo® is a Category 1 new drug submitted by Trinomab. As an upgraded, next-generation "tetanus shot" for emergency tetanus prophylaxis in adults, it is administered via intramuscular injection for rapid onset to achieve emergency protection. It requires no skin test, no post-dose observation (for outpatients), and no differentiation by body weight or wound size, achieving full-course protection with a single injection and single dose.

In the clinical study of this drug, the EClinCloud eCOA solution provided strong support, helping improve the efficiency and quality of clinical trial data collection, providing more accurate and reliable evidence for drug development, and facilitating the efficient and smooth conduct of the study.

Xintituo®'s successful market launch will provide patients with a more accessible and competitive new therapy and has also set an innovative benchmark in the field of clinical research. As a key partner in technology enablement, EClinCloud will continue to provide pharmaceutical companies with reliable digital solutions to advance the intelligent transformation of clinical trials and accelerate the drug development process.

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.